logo
Plus   Neg
Share
Email

Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts

Amgen (AMGN) has entered into a strategic collaboration with BeiGene that will accelerate Amgen's plans to expand its oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company. Amgen will acquire a 20.5 percent stake in BeiGene for approximately $2.7 billion. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ.

Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion. Amgen will pay royalties to BeiGene on the sales of these products outside of China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition. Walt Disney Co.'s (DIS) streaming service Disney+ will be launched on March 24 in the UK and other markets in the Western Europe, one week earlier than originally planned on March 31. Pricing also been confirmed at 5.99 pounds/6.99 euros per month or 59.99 pounds/69.99 euros for an annual subscription....
Follow RTT
>